Pastor Susana, Coll Elisabeth, Rodríguez-Ribera Lara, Stoyanova Elitsa, Corredor Zuray F, Marcos Ricard
Grup de Mutagènesi, Departament de Genètica i de Microbiologia, Edifici Cn, Universitat Autònoma de Barcelona, Bellaterra, Cerdanyola del Vallès, 08193, Spain.
CIBER Epidemiología y Salud Pública, ISCIII, Spain.
Environ Mol Mutagen. 2018 May;59(4):302-311. doi: 10.1002/em.22170. Epub 2018 Jan 23.
End-stage renal disease (ESRD) patients present high levels of phosphorus and calcium products in serum, which contribute to the development of vascular calcification and cardiovascular disease, and to low iron stores and carnitine deficiency. For these reasons, ESRD patients are generally supplemented with different medicines. Some of the most common treatments include the use of Carnicor, Venofer, and Sevelamer drugs. Carnicor is used as a source of L-carnitine, acting as antioxidant and neuroprotector. Venofer is used to reduce the deficit of iron. Sevelamer is used to treat hyperphosphatemia. To determine the potential harmful genotoxic effects of these drugs, a group of 214 patients included in a hemodialysis program with different intakes of Carnicor, Venofer, and Sevelamer were evaluated. The levels of basal and oxidative DNA damage, as well as chromosomal damage, were measured in all individuals using the comet and the micronucleus assays, respectively. Our results indicate that Carnicor administration was associated with low but significant increases in the frequency of basal DNA damage and micronuclei. Environ. Mol. Mutagen. 59:302-311, 2018. © 2018 Wiley Periodicals, Inc.
终末期肾病（ESRD）患者血清中磷和钙产物水平较高，这会导致血管钙化和心血管疾病的发生，还会导致铁储备不足和肉碱缺乏。由于这些原因，ESRD患者通常会补充不同的药物。一些最常见的治疗方法包括使用卡尼可（Carnicor）、维诺非（Venofer）和司维拉姆（Sevelamer）药物。卡尼可作为左旋肉碱的来源，具有抗氧化和神经保护作用。维诺非用于减少铁缺乏。司维拉姆用于治疗高磷血症。为了确定这些药物潜在的有害基因毒性作用，对一组214名参加血液透析项目且服用不同剂量卡尼可、维诺非和司维拉姆的患者进行了评估。分别使用彗星试验和微核试验测量了所有个体的基础DNA损伤水平、氧化DNA损伤水平以及染色体损伤水平。我们的结果表明，服用卡尼可与基础DNA损伤频率和微核频率的低但显著增加有关。《环境与分子突变》59:302 - 311, 2018。© 2018威利期刊公司。
